Skip to content
WeightLossDrugsGuide

Independent educational reference. Not a pharmacy, medical provider, or telehealth clinic — and not a substitute for medical advice.

Brand product · Liraglutide

Saxenda: FDA Status, Uses, Safety and Cost

FDA ApprovedApproved for chronic weight managementSubcutaneous injection (prefilled pen) · Once daily

Single receptor target (GLP-1)

Editorially reviewed by the editorial teamLast updated August 12, 2026Sources last verified August 12, 2026

What Saxenda is

Saxenda is Novo Nordisk’s brand of liraglutide approved for chronic weight management — the first GLP-1 medication approved for weight management (2014). It is injected once daily, unlike the newer once-weekly options, and generic liraglutide products have been approved by the FDA.

Key facts

Key facts about Saxenda
Generic (active ingredient)Liraglutide
Brand namesSaxenda
Drug classGLP-1 receptor agonist
ManufacturerNovo Nordisk
FDA statusFDA ApprovedApproved for chronic weight management
AdministrationSubcutaneous injection (prefilled pen)
FrequencyOnce daily
Approval dateDecember 2014 (adults); December 2020 (adolescents 12+)
Prescription requiredYes
Official labelPrescribing information (DailyMed)

What Saxenda is approved for

  • Chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity
  • Chronic weight management in pediatric patients aged 12 and older with obesity (per label criteria)

How Saxenda works

Liraglutide mimics the GLP-1 hormone, acting on appetite-regulation pathways and slowing gastric emptying to reduce calorie intake.

  1. 1

    Medication binds

    A GLP-1 receptor agonist activates the receptor for the natural GLP-1 hormone.

  2. 2

    Signals are sent

    Appetite-regulating areas of the brain are affected, increasing fullness.

  3. 3

    Stomach slows

    Gastric emptying slows, so food stays in the stomach longer.

  4. 4

    Intake falls

    Per FDA labeling, weight reduction happens mainly through eating fewer calories.

Simplified schematic of the mechanism described in FDA labeling for GLP-1 receptor agonists. Individual products differ — read the prescribing information linked on each drug page.

Administration

Saxenda is given by subcutaneous injection (prefilled pen), once daily.

We do not publish dosing guidance

Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.

Important safety information

Boxed Warning — the FDA’s most serious warning

Risk of thyroid C-cell tumors: caused thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether this occurs in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Summarized from the product’s FDA prescribing information. Read the full label, linked in Sources below.

Contraindications (who should not take it)

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnancy
  • Known serious hypersensitivity to liraglutide or product components

Summarized from the FDA prescribing information. This is not the complete list — see the full label.

Common adverse reactions from official labeling

  • Nausea
  • Diarrhea
  • Constipation
  • Vomiting
  • Injection site reactions
  • Headache
  • Hypoglycemia
  • Dyspepsia (indigestion)
  • Fatigue
  • Dizziness

The most common adverse reactions listed in the product’s FDA prescribing information. Frequency and full adverse-reaction data are in the label.

Brand and generic relationships

Saxenda is a brand product containing the active ingredient liraglutide.

Cost and access

  • Prescription only.
  • FDA-approved generic liraglutide may offer a lower-cost route to the same active ingredient — availability varies by pharmacy.
  • Novo Nordisk savings offers may apply for eligible patients; verify current terms.

Why we don't publish a price

List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.

Insurance considerations

  • Subject to the same weight-management exclusions as other GLP-1 weight-loss drugs; coverage varies by plan.

More detail: how insurance coverage works for weight-loss medication.

Frequently asked questions

Is Saxenda the same as Wegovy?
No. Both are Novo Nordisk GLP-1 injections approved for weight management, but Saxenda is liraglutide (once daily) and Wegovy is semaglutide (once weekly).
Is there a generic Saxenda?
The FDA has approved generic liraglutide products. Whether a generic equivalent to Saxenda is stocked varies by pharmacy — confirm locally.

Sources

  1. Saxenda prescribing information (DailyMed, NIH) DailyMed/NIH. Link last verified August 12, 2026.
  2. Drugs@FDA database FDA. Link last verified August 12, 2026.
  3. Saxenda official site (Novo Nordisk) Manufacturer. Link last verified August 12, 2026.
Editorially reviewed by the editorial teamLast updated August 12, 2026Sources last verified August 12, 2026

Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.